Zacks Investment Research·20h ago
CareDx Completes Naveris Acquisition and Expands Oncology ReachCDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx, Inc(CDNA)Earnings, Financials & Key Ratios
CDNA•NASDAQ
$28.31
Price updated Jul 7, 2026
AboutCareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Show more
- Revenue$380M+13.8%
- EBITDA-$600K-101.0%
- Net Income-$21M-140.6%
- EPS (Diluted)-0.40-143.0%
- Gross Margin66.99%-0.2%
- EBITDA Margin-0.16%-100.9%
- Operating Margin-5.53%-145.3%
- Net Margin-5.62%-135.7%
- ROE-6.27%-138.1%
CDNA Price & Volume
CareDx, Inc (CDNA) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Persistent Margin Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strained
Financial:Adequate
Cash Flow:Improving
Primary Risk:Medicare reimbursement policy volatility
Key Thesis Takeaways
- CareDx demonstrates a compelling growth trajectory with 39.0% year-over-year revenue expansion in 2026Q1, yet the firm struggles to translate this top-line momentum into consistent GAAP profitability.
- While the company has successfully deleveraged its balance sheet to a 0.06 debt-to-equity ratio, investors should remain cautious regarding the impact of Medicare reimbursement volatility on long-term cash flow stability.
- Future performance hinges on the firm's ability to scale operations effectively while mitigating the persistent drag of $9.8M in quarterly stock-based compensation.
Verdict Logic
while the company shows accelerating revenue growth of 39.0%, the lack of consistent GAAP profitability and the $732.5M accumulated deficit warrant a cautious approach until operating leverage is clearly established.
CDNA Growth Metrics
CareDx, Inc (CDNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years29.72%
5 Years14.59%
3 Years5.68%
TTM19.17%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-114.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-114.57%
Return on Capital
10 Years-26.43%
5 Years-13.34%
3 Years-14.34%
Last Year-5.8%
CDNA Recent Earnings
CareDx, Inc (CDNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.34+209.1%
$0.11
Rev
$118M+15.4%
$102M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.12+503.0%
$0.02
Rev
$108M+5.0%
$103M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.28+115.4%
$0.13
Rev
$100M-2.6%
$103M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.10-16.7%
$0.12
Rev
$87M-9.0%
$95M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.34vs $0.11+209.1% | $118Mvs $102M+15.4% |
| Q1 2026 | Feb 24, 2026 | $0.12vs $0.02+503.0% | $108Mvs $103M+5.0% |
| Q4 2025 | Nov 4, 2025 | $0.28vs $0.13+115.4% | $100Mvs $103M-2.6% |
| Q3 2025 | Aug 6, 2025 | $0.10vs $0.12-16.7% | $87Mvs $95M-9.0% |
Based on last 12 quarters of dataView full earnings history →
Latest CDNA News
Recent stock market news and headlines for CareDx, Inc (CDNA)
Seeking Alpha·1 day ago
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics CompounderCareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
Business Wire·6 days ago
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty OncologyBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.
Business Wire·Jun 30, 2026
CareDx Announces Completion of Sale of Lab Products Business to Eurobio ScientificBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearan.
The Motley Fool·Jun 21, 2026
CareDx's CEO Sells 17K SharesThe CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.
Peers Comparison
Key metrics vs top competitors for CareDx, Inc (CDNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.31 | $1.46B | -70.78 | 13.79% | -5.62% | -6.27% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $1.97 | $22.8M | -40.04 | 71.61% | 5.34% | 0.66% | — |
Compare CDNA vs Peers
CareDx, Inc (CDNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDNA SEC Filings & Documents
CareDx, Inc (CDNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Feb 24, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when CDNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CDNA Frequently Asked Questions
CareDx, Inc (CDNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CareDx, Inc's revenue?
CareDx, Inc (CDNA) reported $412.8M in revenue for fiscal year 2025. This represents a 1919% increase from $20.5M in 2012.
How fast is CareDx, Inc growing?
CareDx, Inc (CDNA) grew revenue by 13.8% over the past year. This is steady growth.
Is CDNA profitable?
CareDx, Inc (CDNA) reported a net loss of $8.2M for fiscal year 2025.
Dividend & Returns
What is CDNA's return on equity?
CareDx, Inc (CDNA) has a return on equity (ROE) of -6.3%. Negative ROE indicates the company is unprofitable.
What is CareDx, Inc's free cash flow?
CareDx, Inc (CDNA) generated $65.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.